HebaBiz Biotech Obtains FDA Clearance to Trial Cancer Drug Against Aggressive Brain Tumor
Glioblastoma (GBM) is the most common and aggressive form of brain tumor with a poor prognosis. Existing treatment includes surgery, followed by radiotherapy, and chemotherapy. Yet, several patients develop resistance to treatments, suffer from relapse, and die, creating a significant unmet need in this area.
At this juncture, Beijing-based HebaBiz Biotech announces that the FDA has accepted IND for its innovative anti-cancer drug for Glioblastoma trials in the US.
At this juncture, Beijing-based HebaBiz Biotech announces that the FDA has accepted IND for its innovative anti-cancer drug for Glioblastoma trials in the US.
GO Prime with only $1.49 now
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02